VanEck Biotech ETF BBH
255.57 USD +1.07 (+0.42%)
At closeNov 4, 2026, 4:00 AM EST
246.00 -9.57 -3.74%
Pre-market · Nov 4, 4:00 AM ET
255.09 Day range 257.58
178.78 52-week range 262.60
- YTD
- +35.04%
- 1 year
- +43.04%
- Market cap
- 520.48M
- EPS (ttm)
- 8.48
- P/E ratio
- 30.14
- YTD return
- +35.04%
- 1-year return
- +43.04%
- Volume
- 19.77K
- Avg volume
- 11.69K
- Open
- 256.08
- Previous close
- 254.50
- Day's range
- 255.09 – 257.58
- 52-week range
- 178.78 – 262.60
2Y +85.16 (+49.97%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 167.95
- 200-day average
- 169.82
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
ETFs That You May Consider Amid a Strengthening Biotech Outlook 
Why Healthcare ETFs Are Hovering Around One-Year Highs 
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? 
Biotech ETF (BBH) Hits New 52-Week High 
BBH Capital Partners Private Equity Exits The Granite Group 
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH 
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma 
Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? 
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate 
Should You Invest in the VanEck Biotech ETF (BBH)?
Your note
Sign in to keep a note on BBH — it syncs with the Stock Master app.